Kane Biotech (TSE:KNE) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kane Biotech Inc. has entered into a global licensing agreement with Omni Bioceutical Innovations for the distribution of its coactiv+™ scalp care product line. The five-year deal allows Omni to market Kane’s innovative scalp detoxifier under their brand, targeting the medical aesthetics market. The partnership is poised to leverage the product’s proven efficacy in addressing common scalp conditions without harsh chemicals.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.